With the recent medical classification of adult ADHD and potentially twice the number of patients compared to pediatric ADHD, manufacturers are seeking new indications in this expanding and lucrative market. Lilly's Strattera was the first drug to exploit this, and is forecast to reach blockbuster status by 2006. Consequently, manufacturers will need to differentiate their products from Strattera.

Scope

Overview of the epidemiology of adult ADHD, with an assessment of the untapped patient potential
Discussion of the problems facing physicians in the diagnosis of adult ADHD
Analysis of the current market leaders and primary contenders for market entry, with adult ADHD-specific market forecasts
Exploration of product positioning and life-cycle management strategies currently used by Strattera, Adderall XR and Concerta

Report Highlights

Strattera was the first drug approved for the treatment of adult ADHD in November 2002. Since launch Strattera has a steady sales increase from $55m in Q1 2003 to $133m in Q4 2003, and Datamonitor has forecast Strattera to reach blockbuster status by 2006.

Shire's Adderall XR recently received an approvable letter from the FDA for adult ADHD and J&J's Concerta is currently in Phase III with an expected launch in 2005. Datamonitor forecasts that both drugs will see an increase in sales from gaining an indication for this market, although both will also experience a decline in revenues post 2005.

Approximately 75% of adults with ADHD present with a comorbid condition, of which anxiety and depressive disorders predominate. Datamonitor has highlighted two drug classes, which may benefit from further investigation of the treatment of such comorbidities in order to increase their market share in the adult ADHD market.

Reasons to Purchase

Analyze the commercial viability of the adult ADHD market, based on estimated patient numbers
Develop market entry and consolidation strategies through an understanding of key unmet needs in the market
Identify and assess novel R&D compounds in the adult ADHD pipeline

EXECUTIVE SUMMARY

Introduction
Scope and coverage of the Brief
Key findings about the the topic
Strattera was the first drug approved for the treatment of adult ADHD in November 2002. Since launch, Strattera sales have steadily increased from $55m in Q1 2003 to $133m in Q4 2003, and Datamonitor expects Strattera to reach blockbuster status by 2006.
Shire's Adderall XR recently received an approvable letter from the FDA for an indication in adult ADHD and J&J's Concerta is currently in Phase III with an expected launch in 2005. Datamonitor forecasts that both drugs will see an increase in sales from gaining an indication for this market although both will also experience a decline in revenues post 2005.
It is currently estimated that approximately 75% of adults with ADHD present with a comorbid condition, of which anxiety and depressive disorders predominate. Datamonitor has highlighted two drug classes that may benefit from further investigation of the treatment of such comorbidities in order to increase their market share in the adult ADHD market.

DISEASE OVERVIEW

Disease definition: Etiology of ADHD; Structural abnormalities; Genetic predisposition; Neurotransmitter dysfunction; Dopaminergic genes; DSM-IV diagnostic criteria of ADHD; Progression of symptoms from pediatric to adult ADHD
Epidemiology: Prevalence of adult ADHD; Segmentation of adult ADHD; Gender; Comorbidities; Anxiety and mood comorbidities; Substance abuse

DIAGNOSIS

Diagnostic guidelines: History of symptoms; Diagnostic rate

TREATMENT

Treatment guidelines
Pharmacological treatment
Stimulants: Stimulants for adult ADHD; Adderall XR; The clinical data supporting Adderall for the treatment of adult ADHD; Adderall XR forecast; Opportunities for Shire and Adderall XR; Concerta; Concerta forecast; Opportunities for J&J and Concerta
Non-stimulants: Strattera; The clinical data supporting Strattera for the treatment of adult ADHD; Strattera forecast; Opportunuities for Lilly and Strattera
Antidepressants
Off-label prescribing

PIPELINE ANALYSIS

Unmet needs
Pipeline drugs: Methypatch; SPD-503
Backlash to adult ADHD?

APPENDIX

Bibliography
Websites: Research methodology; Disclaimer

List of Tables

Table 1: Symptoms of ADHD in children and adults.
Table 2: Comorbid disorders with ADHD
Table 3: ADHD diagnostic tools
Table 4: Stimulants for ADHD
Table 5: Adderall sales forecast to 2008
Table 6: Concerta sales forecast to 2008
Table 7: Non-stimulants for ADHD
Table 8: Strattera sales forecast to 2008
Table 9: Forecast sales for ADHD drugs approved for both child and adult markets, 2002-08
Table 10: Late stage pipeline ADHD drugs, 2004

List of Figures

Figure 1: Prevalence of adults with ADHD in the general population across the seven major markets, 2004
Figure 2: Assessment of adults presenting with symptoms of ADHD
Figure 3: Diagnosis rate of ADHD across the seven major markets, 2004
Figure 4: ADHD pharmacological treatment algorithm
Figure 5: ADHD patients receiving pharmacological treatment, 2004
Figure 6: Adderall study for adult ADHD
Figure 7: Adderall XR study in adult ADHD
Figure 8: Adderall sales forecast to 2008
Figure 9: Release rate of Concerta and resulting serum levels
Figure 10: Concerta sales forecast to 2008
Figure 11: Strattera sales forecast to 2008
Figure 12: Sales of ADHD drugs ($m), Q3 2000(Q2 2003
Figure 13: Methypatch sales forecast to 2008
Figure 14: Lilly's Adult Self-Report Scale